Тофацитиниб (Tofacitinib)
Международное непатентованное наименование
Тофацитиниб (Tofacitinib)
Торговое наименование
Xeljanz, Jakvinus, Tofacinix
Производитель, страна
Pfizer Inc., USA
Механизм действия
Tofacitinib is an inhibitor of Janus kinases (JAK). This inhibition prevents the activation of the signal transducers and activators of transcription (STAT) which may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha and -beta, and may prevent both the inflammatory response and the inflammation-induced damage caused by certain disease such as severe COVID-19.
FDA-approved since 2012, approved to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis
Клинические исследования
1.
Название протокола
TOFAcitinib in Patients With Early Onset SARS-CoV2 Interstitial Pneumonia
Дата начала и окончания КИ
April 10, 2020 - July 10, 2020
Название организации, проводящей КИ
Università Politecnica delle Marche
Страны
Italy
Фаза
II
Кол-во пациентов
50